BRPI0815415A2 - Marcador preditivo para tratamento inibidor de egfr - Google Patents

Marcador preditivo para tratamento inibidor de egfr

Info

Publication number
BRPI0815415A2
BRPI0815415A2 BRPI0815415-5A2A BRPI0815415A BRPI0815415A2 BR PI0815415 A2 BRPI0815415 A2 BR PI0815415A2 BR PI0815415 A BRPI0815415 A BR PI0815415A BR PI0815415 A2 BRPI0815415 A2 BR PI0815415A2
Authority
BR
Brazil
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive marker
predictive
marker
Prior art date
Application number
BRPI0815415-5A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Delmar
Barbara Klughammer
Verena Lutz
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0815415A2 publication Critical patent/BRPI0815415A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0815415-5A2A 2007-08-14 2008-08-07 Marcador preditivo para tratamento inibidor de egfr BRPI0815415A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114292 2007-08-14
PCT/EP2008/006513 WO2009021674A1 (fr) 2007-08-14 2008-08-07 Marqueurs prédictifs pour un traitement par un inhibiteur d'egfr

Publications (1)

Publication Number Publication Date
BRPI0815415A2 true BRPI0815415A2 (pt) 2015-02-03

Family

ID=39884813

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815415-5A2A BRPI0815415A2 (pt) 2007-08-14 2008-08-07 Marcador preditivo para tratamento inibidor de egfr

Country Status (9)

Country Link
EP (1) EP2188391A1 (fr)
JP (1) JP2010535517A (fr)
KR (1) KR20100037637A (fr)
CN (1) CN101778954A (fr)
AU (1) AU2008286407A1 (fr)
BR (1) BRPI0815415A2 (fr)
CA (1) CA2695485A1 (fr)
MX (1) MX2010001571A (fr)
WO (1) WO2009021674A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121238A2 (fr) * 2009-04-17 2010-10-21 Translational Genomics Research Institute (Tgen) Méthodes et kits permettant de prédire le résultat thérapeutique d'inhibiteurs de la tyrosine kinase
CN108732350A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Pla2g6作为指示肝内结节及早期预警肝癌的生物标志物
CN108732351A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Eps8l2作为指示肝内结节及早期预警肝癌的生物标志物
CN108732349A (zh) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 Lta4h作为指示肝内结节及早期预警肝癌的生物标志物
CN110780072B (zh) * 2019-12-09 2021-08-06 四川大学华西医院 Apoo自身抗体检测试剂在制备肺癌筛查试剂盒中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
WO2001079556A2 (fr) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Nouveaux genes, compositions et methodes destines a l'identification, l'evaluation, la prevention, et la therapie de cancers humains
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP2348110B1 (fr) * 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Procede de criblage d'une reponse medicamenteuse des patients atteints de cancer
WO2006101925A2 (fr) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biomarqueurs predictifs de reponse anticancereuse a des inhibiteurs de kinase de recepteur de facteur de croissance epidermique
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US20070128636A1 (en) * 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors

Also Published As

Publication number Publication date
JP2010535517A (ja) 2010-11-25
AU2008286407A1 (en) 2009-02-19
KR20100037637A (ko) 2010-04-09
MX2010001571A (es) 2010-03-15
CN101778954A (zh) 2010-07-14
EP2188391A1 (fr) 2010-05-26
CA2695485A1 (fr) 2009-02-19
WO2009021674A1 (fr) 2009-02-19

Similar Documents

Publication Publication Date Title
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0806898A2 (pt) Inibidores de mek
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0821129A2 (pt) Métodos para a inibição de cicatrização
BRPI0922880A2 (pt) compostos inibidores de quinase
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
FR2911341B1 (fr) Inhibiteur de corrosion
BRPI0815415A2 (pt) Marcador preditivo para tratamento inibidor de egfr
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0815545A2 (pt) Marcadores preditivos para o tratamento com inibidores de egfr
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
BRPI0814257A2 (pt) marcador preditivo para o tratamento do inibidor de egfr
BRPI0814354A2 (pt) Marcador preditivo para tratamento com inibidor de egfr
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
BRPI0715729A2 (pt) inibidores para glyt-1
BRPI0815414A2 (pt) Marcador para o tratamento com inibidor de egfr
BRPI0817361A2 (pt) Marcador preditivo para tratamento com inibidor de egfr
ES2395881T9 (es) Marcador predictivo para el tratamiento de inhibidor de EGFR
BRPI0815546A2 (pt) Marcador preditivo para tratamento com inibidor da egfr
ES1064720Y (es) Guia para persiana
BRPI0815372A2 (pt) marcador preditivo para o tratamento com inibidor do egfr
ES1064561Y (es) Electrovalvula para grifo
BRPI0821270A2 (pt) Métodos para a inibição de cicatrização
ES1067107Y (es) Entresuela para calzado

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired